This refresh
Data-driven refresh July 15, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,233 tickers); 1,782 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. DOCS — Doximity, Inc. · score 90
Health Information Services · price $22.26 · 1Y $24.53 · 5Y $35.91 · 10Y $53.27
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A · P/E 22.7x B+ · PEG 0.59 A-
Why now. DOCS’s AI‑driven clinical assistant Ask is cementing its role as the go‑to evidence hub for U.S. physicians, unlocking repeat usage that fuels compounding revenue. The platform’s 30.4% profit margin and 20.6% ROE show pricing power from a captive professional audience, while 13.1% YoY revenue growth proves the network effect is still expanding. The thesis rests on Ask’s ability to lock in clinicians’ daily workflow, turning each user into a recurring revenue engine.
Moat. The moat comes from the HIPAA‑compliant workflow tools—Ask and Scribe—that embed directly into doctors’ daily practice, creating high switching costs because clinicians rely on the platform for vetted medical information. This entrenched usage translates into pricing leverage, evident in the 30.4% margin and 20.6% ROE, which competitors can’t replicate without building a comparable trusted data pipeline.
Risk. The bear case hinges on the platform’s growth slowing as the market saturates; a 13.1% revenue growth rate is modest for a growth name and any deceleration would pressure the 22.7× P/E. A higher beta of 1.29 amplifies downside if broader tech risk spikes. A breach of the HIPAA compliance shield or a superior AI offering from a larger health‑tech player would erode the switching barrier, and a drop below the 52‑week low of $17.15 would confirm the risk.
Horizon. 1-3 yr $24.53 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $35.91 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $53.27 if current growth sustains into durable earnings power.
2. ADBE — Adobe Inc. · score 89.6
Software - Application · price $224.56 · 1Y $272.48 · 5Y $398.93 · 10Y $591.79
FCF $10.3b A- · Rev +11.5% B · D/E 0.61 C+ · P/E 12.8x A · PEG 0.61 A-
Why now. Adobe's entrenched position across its Digital Media and Digital Experience segments is significantly undervalued by the market, presenting a compelling growth opportunity. With a remarkably low P/E of 12.8 and a PEG Ratio of 0.61, the company is generating substantial free cash flow of $10.3B (TTM) from its critical software platforms. The crux of the bull case rests on the market re-rating this high-profitability, cash-generative business closer to its historical growth-stock multiples as its revenue growth of 11.5% persists.
Moat. Adobe's formidable moat stems from the deep integration of its Digital Media products into the professional workflows of photographers, video editors, and graphic designers, creating high switching costs. Similarly, its Digital Experience segment provides an integrated platform that becomes indispensable for brands managing customer experiences from analytics to commerce. This category leadership and essential utility drive exceptional pricing power, reflected in a robust ROE of 62.8% and a profit margin of 28.7%, making it difficult for competitors to dislodge.
Risk. Bears argue that Adobe's growth could decelerate further if competition intensifies in its core Digital Media or Digital Experience segments, or if enterprise spending on creative and experience solutions tightens. The stock's high beta of 1.43 indicates significant sensitivity to broader market downturns, which could exacerbate any fundamental weakness. A sustained drop in the current 11.5% revenue growth rate or a notable erosion of the 28.7% profit margin would confirm the bear case, signaling a loss of pricing power or market share.
Horizon. 1-3 yr $272.48 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $398.93 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $591.79 if current growth sustains into durable earnings power.
3. INTU — Intuit Inc. · score 89
Software - Application · price $279.70 · 1Y $480.68 · 5Y $703.76 · 10Y $1,044
FCF $7.8b B+ · Rev +15.1% B+ · D/E 0.33 B · P/E 17.1x A- · PEG 0.71 A-
Why now. Intuit’s QuickBooks Online platform is the engine of its growth, delivering 15.1% YoY revenue expansion while the business converts that into a 21.9% profit margin and a 22.2% ROE, all at a modest PE of 17.1x. The combination of sticky SaaS subscriptions and expanding merchant payment processing creates a compounding engine that will keep earnings accelerating for the next decade, making the current price a launchpad for outsized upside.
Moat. The moat lives in the integrated ecosystem of QuickBooks, payroll, and merchant services that lock small‑business owners into a single workflow, creating high switching costs and cross‑sell leverage. This ecosystem fuels the high ROE by allowing Intuit to price premium solutions to a captive customer base that cannot easily replicate the end‑to‑end financial management stack.
Risk. The biggest headwind is the intensifying competition from large cloud ERP players and fintech platforms that could erode QuickBooks’ market share, while Intuit’s valuation remains elevated at a PE of 17.1x despite a decelerating revenue growth outlook. A slowdown to sub‑10% revenue growth or a margin dip below 20% would trigger a re‑rating, and a breach of the 52‑week low ($252.84) would confirm the bear case.
Horizon. 1-3 yr $480.68 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $703.76 at ~20% CAGR — compounding case rests on the competitive position widening. 10 yr $1,044 if current growth sustains into durable earnings power.
4. DLO — DLocal Limited · score 88.9
Software - Infrastructure · price $14.90 · 1Y $17.85 · 5Y $26.13 · 10Y $38.77
FCF $413m C · Rev +46.6% A · D/E 0.20 B+ · P/E 23.3x B+ · PEG 0.50 A
Why now. DLocal’s unified cross‑border payment platform for e‑commerce, streaming and ride‑hailing merchants is exploding, delivering 46.6% YoY revenue growth, an elite 34.6% ROE and a razor‑thin PEG of 0.5 that signals deep‑seated compounding; the engine is the pay‑in suite that locks merchants into a single global gateway, ensuring growth persists as digital commerce expands.
Moat. The moat lives in DLocal’s end‑to‑end pay‑in and pay‑out stack for platforms, which bundles hundreds of local cards, bank transfers and alternative methods into one API, creating high switching costs and a network effect that rivals cannot replicate quickly; its low debt (D/E 0.2) lets it price competitively while maintaining a 34.6% ROE driven by pricing power in cross‑border payments.
Risk. The bull case hinges on continued double‑digit growth, but the stock trades at a forward P/E of 23.3 for a company whose growth could decelerate, and any margin compression would make that multiple look stretched; a slowdown in emerging‑market e‑commerce or a pricing war would push the P/E to historic highs and validate the bear view. A sustained dip below the 52‑week low of $9.81 would be the red flag.
Horizon. 1-3 yr $17.85 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $26.13 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $38.77 if current growth sustains into durable earnings power.
5. NBIX — Neurocrine Biosciences, Inc. · score 87.2
Drug Manufacturers - Specialty & Generic · price $172.05 · 1Y $199.27 · 5Y $291.76 · 10Y $432.80
FCF $831m C+ · Rev +28.6% A- · D/E 0.14 B+ · P/E 26.5x B · PEG 0.50 A
Why now. NBIX is a compounding powerhouse because its flagship neuro‑movement drugs—INGREZZA for tardive dyskinesia and Orilissa for endometriosis—are entrenched in high‑margin specialty niches, fueling a 28.6% YoY revenue growth while preserving a 21.6% profit margin and a PEG of 0.5. This rare blend of growth and profitability drives a near‑20% ROE, ensuring cash can be reinvested into the pipeline and shareholder returns, and the thesis hinges on the continued expansion of these differentiated therapies.
Moat. The moat rests on FDA‑approved, first‑in‑class indications for INGREZZA and Orilissa, backed by robust patents and a specialist sales force that locks in neurologists and gynecologists who face high switching costs to alternative off‑label treatments. Pricing power stems from the lack of direct competitors in tardive dyskinesia and endometriosis, allowing NBIX to sustain its 21.6% margin and fund further R&D without eroding returns.
Risk. The bear case points to the elevated valuation—P/E of 26.5 on a growth rate that may decelerate if pipeline candidates like NBI-1076986 fail to clear regulatory hurdles—combined with a modest debt‑to‑equity of 0.14 that offers little cushion against a costly clinical setback. A missed trial or delayed launch would compress margins and force the stock toward its 52‑week low of $122.14, confirming the downside.
Horizon. 1-3 yr $199.27 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $291.76 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $432.80 if current growth sustains into durable earnings power.
6. LRN — Stride, Inc. · score 86.9
Education & Training Services · price $83.39 · 1Y $95.90 · 5Y $140.40 · 10Y $208.28
FCF $414m C · Rev +10.9% B · D/E 0.33 A- · P/E 13.1x A- · PEG 0.51 A-
Why now. Stride, Inc. is a high-quality compounder trading at a deep discount, driven by persistent demand for its comprehensive online educational services. With a remarkably low PEG ratio of 0.51 and a P/E of just 13.1x TTM earnings, the market is severely underpricing a business that delivered 10.9% FY YoY revenue growth and generated a robust $414m in free cash flow. The crux is that its integrated offerings for virtual and blended public schools continue to capture market share, yet the valuation suggests skepticism that is unwarranted by the fundamentals.
Moat. Stride's durable edge stems from its integrated package of proprietary and third-party online curriculum, software systems, and professional expertise, which creates high switching costs for schools and districts. These technology-based products and services enable clients to attract, enroll, educate, track progress, support, and facilitate individualized learning for students, making it difficult for competitors to dislodge. The company's strong 18.8% Return on Equity reflects the stickiness and efficiency of its comprehensive solutions in the education sector.
Risk. The primary bear case against Stride centers on potential saturation or policy shifts within the online education market, which could decelerate its core growth. Despite a healthy 10.9% revenue growth, the stock trades significantly below its 52-week high of $171.17, suggesting investor concerns about the sustainability of its expansion or perceived competitive pressures in the general education market. A sustained deceleration in new enrollments or contract renewals for its virtual and blended public school offerings would confirm the bear case and erode the bull thesis.
Horizon. 1-3 yr $95.90 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $140.40 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $208.28 if current growth sustains into durable earnings power.
7. NVDA — NVIDIA Corporation · score 85.5
Semiconductors · price $212.50 · 1Y $301.62 · 5Y $441.60 · 10Y $655.09
FCF $119.1b A · Rev +70.7% A · D/E 0.07 A- · P/E 32.6x B · PEG 0.65 A-
Why now. NVIDIA's Compute & Networking segment is the engine of the AI data‑center boom, and its revenue is exploding at 70.7% YoY while delivering a 63% profit margin and generating $119.1 B of free cash flow – a cash‑rich moat that fuels relentless reinvestment. The combination of a PE of 32.6 and a 58‑analyst consensus 1‑yr target of $301.62 implies the market already values the near‑term surge, but the real catalyst is the compounding AI spend that will keep the growth engine humming for years. The thesis rests on sustained AI‑driven data‑center demand that keeps revenue compounding at double‑digit rates.
Moat. NVIDIA's dominance in GPU‑accelerated AI hardware creates a high switching cost for data‑center customers, reinforced by proprietary CUDA software that locks in ecosystem lock‑in. Its ROE of 81.7% stems from pricing power in a market where no rival can match the performance‑per‑watt of its Compute & Networking platforms, and a debt‑to‑equity of just 0.07 gives it financial flexibility to out‑spend competitors on R&D.
Risk. The stock trades at a lofty PE of 32.6 and a beta of 2.21, meaning any slowdown in AI spend or a broader market pullback could hammer valuation. If revenue growth falls below the 50% threshold or profit margins dip under 55%, the premium valuation becomes untenable. A confirmed deceleration in the Compute & Networking segment would trigger a sharp re‑rating and break the bull case.
Horizon. 1-3 yr $301.62 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $441.60 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $655.09 if current growth sustains into durable earnings power.
8. EXLS — ExlService Holdings, Inc. · score 85.4
Information Technology Services · price $27.58 · 1Y $40.13 · 5Y $58.75 · 10Y $87.15
FCF $297m C · Rev +13.4% B+ · D/E 0.67 C+ · P/E 17.6x A- · PEG 0.91 B+
Why now. EXLS is riding a secular surge in AI‑powered insurance operations, where its claims‑management and underwriting analytics platform is locking in multi‑year contracts that compound earnings. The business is growing revenue at 13.4% YoY, converting that into a rock‑solid ROE of 32.3% while trading at a sub‑1.0 PEG of 0.91, proving the growth is cheap and sustainable. The thesis rests on the continued digitization of insurance and the high‑margin, recurring cash flows that fuel compounding for years to come.
Moat. EXLS’s AI‑driven analytics suite for insurance creates deep switching costs: carriers embed its claims‑management and risk‑analytics tools into core workflows, making migration costly and time‑consuming. This entrenched position fuels pricing power, which is reflected in the 32.3% ROE, and the proprietary data set it amasses cannot be replicated quickly by new entrants.
Risk. The bull case hinges on sustained insurance spend; a slowdown or a win by a larger tech rival could compress margins and stall growth, leaving the stock vulnerable at a still‑elevated P/E of 17.6 and a debt‑to‑equity of 0.67. A breach of the 52‑week low ($24.85) would signal market doubt and could trigger a sell‑off, confirming the bear thesis.
Horizon. 1-3 yr $40.13 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $58.75 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $87.15 if current growth sustains into durable earnings power.
9. HRMY — Harmony Biosciences Holdings, Inc. · score 85.3
Biotechnology · price $34.90 · 1Y $44.91 · 5Y $65.75 · 10Y $97.54
FCF $342m C · Rev +20.7% A- · D/E 0.18 B+ · P/E 14.1x A- · PEG 0.65 A-
Why now. Harmony Biosciences presents a compelling growth story, driven by the continued expansion of WAKIX for narcolepsy and its promising pipeline targeting rare neurological diseases like Prader-Willi Syndrome and Myotonic Dystrophy. With a robust 20.7% FY YoY revenue growth and a remarkably low 0.65 PEG ratio, the company is generating substantial $342m in free cash flow, indicating significant undervaluation for a commercial-stage pharmaceutical. The thesis hinges on HRMY's ability to translate its current profitability and pipeline progress into sustained market share gains and new therapeutic approvals.
Moat. Harmony Biosciences' durable edge stems from WAKIX (pitolisant), a therapy with a novel mechanism of action addressing excessive daytime sleepiness in narcolepsy, which provides a distinct competitive advantage in a specialized market. This core asset is further bolstered by a pipeline focused on rare neurological diseases like Prader-Willi Syndrome and Myotonic Dystrophy, leveraging the same molecule and creating a high barrier to entry due to the significant regulatory and development costs inherent in pharmaceutical innovation. The company's focus on niche, high-need areas allows it to command pricing power and maintain its healthy 16.2% profit margin.
Risk. The primary bear case for Harmony Biosciences centers on its pipeline concentration and the inherent risks of clinical development, particularly with Pitolisant in Phase 3 for Prader-Willi Syndrome and Phase 2 for Myotonic Dystrophy. The wide analyst target range of $28–$85 underscores the market's uncertainty regarding the successful commercialization of these future therapies. A significant clinical trial failure or a delay in regulatory approval for any of its pipeline assets would severely impact future growth prospects and confirm the skepticism around its long-term valuation.
Horizon. 1-3 yr $44.91 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $65.75 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $97.54 if current growth sustains into durable earnings power.
10. ADMA — ADMA Biologics, Inc. · score 84.5
Biotechnology · price $8.68 · 1Y $17.60 · 5Y $25.77 · 10Y $38.23
FCF $108m C · Rev +11.0% B · D/E 1.11 C · P/E 12.8x A · PEG 0.65 A-
Why now. ADMA’s moat lies in its specialty plasma‑derived IVIG franchise—BIVIGAM and ASCENIV—serving the high‑margin primary humoral immunodeficiency market, and that franchise is now cash‑generating at a PE of 12.8x, a ROE of 42.4% and a profit margin of 32.4%. Those fundamentals, combined with 11% YoY revenue growth, give the business a compounding engine that can sustain double‑digit earnings expansion for years to come. The thesis hinges on scaling IVIG volumes while preserving margin, which will drive the stock toward the consensus 1‑yr target.
Moat. ADMA controls the full plasma‑to‑product chain through its ADMA BioManufacturing and Plasma Collection Centers, creating a captive supply of high‑purity plasma that rivals cannot replicate quickly. This vertical integration underpins pricing power in the IVIG category, reflected in the 32.4% profit margin and fuels the 42.4% ROE, giving the company a durable cost advantage and barrier to entry.
Risk. The bear case centers on the concentration risk of the IVIG market—any successful biosimilar entrant could erode pricing power, and ADMA’s debt‑to‑equity of 1.11 signals leverage that could strain cash flow if margins compress. A widening P/E above the current 12.8x or a slowdown in revenue growth below 11% would validate the downside, and a breach of the 52‑week low ($7.21) would trigger a sell‑off.
Horizon. 1-3 yr $17.60 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $25.77 at ~24% CAGR — compounding case rests on the competitive position widening. 10 yr $38.23 if current growth sustains into durable earnings power.
11. CARG — CarGurus, Inc. · score 83.6
Auto & Truck Dealerships · price $35.66 · 1Y $37.38 · 5Y $54.73 · 10Y $81.20
FCF $293m C · Rev +14.0% B+ · D/E 0.79 B · P/E 18.8x B · PEG 1.04 B+
Why now. CarGurus’ Digital Deal platform is turning its massive dealer network into a high‑margin, recurring‑revenue engine, fueling 14% YoY revenue growth while delivering a 15.9% profit margin and a ROE of 62.9%. The business’s free‑cash‑flow generation of $293 m on a $3.2 b market cap gives it a healthy cash yield that can be reinvested into expanding Digital Deal listings, compounding earnings at a sustainable pace. The thesis hinges on the continued capture of online car‑shopping traffic into this integrated dealer‑subscription model, which should keep the growth‑rate and cash conversion high.
Moat. CarGurus protects its advantage through the Digital Deal and Dealer Subscription suite that lock dealers into a data‑rich, lead‑generation platform, creating switching costs for both dealers and shoppers. The 62.9% ROE stems from pricing power in a category‑lead position where advertisers and dealers pay premium fees for access to the platform’s audience, a moat that rivals cannot replicate without building a comparable network from scratch.
Risk. The stock trades at a forward P/E of 18.8 with a beta of 1.18, indicating that any slowdown in revenue growth or margin compression could quickly erode valuation multiples. A debt‑to‑equity of 0.79 adds leverage risk if the auto market softens, and a deceleration from the current 14% YoY growth would pressure the 15.9% margin. A sustained drop in dealer subscription spend or a shift of traffic to competing marketplaces would trigger the bear case, with the share price falling back toward the 52‑week low of $26.39 as confirmation.
Horizon. 1-3 yr $37.38 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $54.73 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $81.20 if current growth sustains into durable earnings power.
12. EPAM — EPAM Systems, Inc. · score 83.3
Information Technology Services · price $85.93 · 1Y $135.94 · 5Y $199.03 · 10Y $295.25
FCF $544m C+ · Rev +14.2% B+ · D/E 0.08 B+ · P/E 12.3x A · PEG 0.44 A
Why now. EPAM’s digital platform engineering franchise is locked into a wave of enterprise cloud migrations, and its 14.2% revenue growth proves the spend is accelerating. The PEG ratio of 0.44 signals massive upside relative to earnings growth, while $544 m of free cash flow gives it the runway to reinvest and outpace peers. The thesis rests on the compounding power of its end‑to‑end engineering services as more firms shift to cloud‑native architectures.
Moat. EPAM’s moat lies in its integrated engineering‑to‑operations model that embeds deep code, cloud, AI and cybersecurity expertise into each client’s core systems, creating high switching costs. Its low debt‑to‑equity of 0.08 lets it price competitively while maintaining a solid ROE of 11.3%, reflecting efficient capital use in a high‑margin services niche.
Risk. The biggest headwind is the market’s sensitivity to tech cycles; EPAM’s beta of 1.43 makes its stock vulnerable to broader risk‑off moves, and a slowdown in enterprise cloud spend could trim the 14.2% growth rate. A breach of the 52‑week low at $73.06 would signal that the growth narrative is fading and could trigger a sell‑off.
Horizon. 1-3 yr $135.94 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $199.03 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $295.25 if current growth sustains into durable earnings power.
13. RMD — ResMed Inc. · score 82.9
Medical Instruments & Supplies · price $198.57 · 1Y $253.73 · 5Y $371.49 · 10Y $551.08
FCF $1.8b C+ · Rev +10.3% B · D/E 0.13 B+ · P/E 19.2x A- · PEG 1.20 B+
Why now. ResMed’s dominance in cloud‑connected sleep diagnostics, anchored by its ApneaLink Air and NightOwl platforms, is fueling a virtuous cycle of recurring software revenue and high‑margin device sales. The business is growing revenue at 10.3% YoY while delivering a 27.4% profit margin and a 23.4% ROE, underscoring sustainable earnings power. The thesis hinges on the continued expansion of home‑based sleep testing, which compounds earnings as adoption accelerates.
Moat. The moat lies in ResMed’s integrated hardware‑software ecosystem for sleep and breathing health, where clinicians and patients are locked into cloud‑based data platforms that drive stickiness and high switching costs. Its pricing power stems from category leadership in home sleep diagnostics, allowing it to command premium pricing that translates into ROE well above 20%.
Risk. The bear case centers on the risk that reimbursement pressure or a disruptive low‑cost competitor erodes margins, exposing the current P/E of 19.2 as overvalued relative to slower growth. A slowdown in revenue growth below 5% or a margin dip under 20% would validate the downside, likely pushing the stock toward its 52‑week low of $180.27.
Horizon. 1-3 yr $253.73 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $371.49 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $551.08 if current growth sustains into durable earnings power.
14. IT — Gartner, Inc. · score 82.8
Information Technology Services · price $133.76 · 1Y $164.23 · 5Y $240.45 · 10Y $356.69
FCF $1.3b C+ · Rev +2.3% C · D/E n/a · P/E 13.2x A- · PEG 0.54 A-
Why now. Gartner presents a compelling growth-at-a-reasonable-price opportunity, evidenced by its incredibly low PEG ratio of 0.54 and a P/E TTM of 13.2. Despite modest recent revenue growth, the company is a free cash flow machine, generating $1.3 billion in TTM FCF against a $9.0 billion market cap. The market is significantly undervaluing the consistent cash generation from its Insights segment's subscription services, which should compound shareholder value over time.
Moat. Gartner's durable edge stems from its Insights segment, which provides mission-critical business and technology insights through subscription services, including access to published content, data, benchmarks, and a network of experts. This creates high switching costs for organizations reliant on Gartner for decision-making, as their proprietary data and expert network are difficult to replicate. The Conferences segment further reinforces this by fostering a unique ecosystem for learning and networking among executives.
Risk. The primary bear case centers on Gartner's decelerating top-line expansion, with revenue growth at just 2.3% FY YoY, raising concerns about market saturation or increased competition in its core business and technology insights. This sluggish growth, coupled with the stock's dramatic fall from its 52-week high of $368.73, suggests investors are already pricing in significant headwinds. A sustained decline in new client acquisition or retention rates within the Insights segment, leading to further pressure on its 11.4% profit margin, would confirm the bear thesis.
Horizon. 1-3 yr $164.23 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $240.45 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $356.69 if current growth sustains into durable earnings power.
15. DXCM — DexCom, Inc. · score 82.6
Medical Devices · price $72.73 · 1Y $85.24 · 5Y $124.80 · 10Y $185.13
FCF $1.4b C+ · Rev +16.1% B+ · D/E 0.47 B · P/E 31.2x C+ · PEG 1.40 B
Why now. DexCom’s G7 platform is rapidly winning the U.S. CGM market, and that rollout fuels a 16.1% YoY revenue growth while delivering a 19.3% profit margin and a 31.5% ROE. The combination of high‑margin CGM subscriptions and expanding indications for G7 15‑Day creates a compounding earnings engine that will keep the growth curve steep for years to come.
Moat. The G7 system locks patients into a subscription model and integrates with DexCom Share and Follow apps, creating high switching costs for both endocrinologists and patients. DexCom’s FDA‑cleared sensor technology and data ecosystem give it a defensible IP edge that rivals cannot replicate quickly, while the 31.5% ROE reflects pricing power from being the category leader in continuous glucose monitoring.
Risk. A bear sees the CGM market heating up with aggressive pricing from competitors, which could compress DexCom’s 31.2 P/E and stall the 16.1% growth rate. If revenue growth falls below 10% and margin pressure pushes profit margin under 15%, the stock could retreat toward its 52‑week low of $54.11. A sustained margin contraction would be the tell‑tale signal that the bull thesis has unraveled.
Horizon. 1-3 yr $85.24 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $124.80 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $185.13 if current growth sustains into durable earnings power.
16. VEEV — Veeva Systems Inc. · score 82.1
Health Information Services · price $193.67 · 1Y $244.59 · 5Y $358.11 · 10Y $531.23
FCF $1.7b C+ · Rev +16.2% B+ · D/E 0.01 A- · P/E 34.3x C+ · PEG 0.86 B+
Why now. Veeva’s Vault CRM suite locks pharma and biotech customers into a single, compliant data backbone, fueling a 16.2% YoY revenue growth while delivering a 28.4% profit margin and a PEG of 0.86, proving the business is growing faster than its valuation suggests. The combination of $1.7 B free cash flow and a near‑zero debt‑to‑equity (0.01) gives the company the financial runway to reinvest in its cloud platform and keep the growth engine humming. The thesis rests on the relentless compounding of subscription revenue from Veeva Commercial Cloud.
Moat. Veeva’s moat stems from its integrated Data Cloud and Vault platform, which embed deep, regulatory‑grade customer data (Veeva OpenData, Veeva Link) into every workflow, creating switching costs that pharma and biotech firms cannot afford to break. This data lock‑in, paired with industry‑specific compliance features, gives Veeva pricing power and a barrier that generic SaaS rivals cannot quickly replicate.
Risk. The stock trades at a lofty PE of 34.3 despite a modest 16.2% revenue growth, implying the market may be over‑paying if growth stalls or margins compress. A slowdown in life‑science cloud adoption or a disruptive competitor could erode the margin cushion, and a breach of the platform’s compliance edge would trigger a sharp re‑rating. The bear case is confirmed if the 52‑week low of $148.05 is breached and the consensus 1‑yr target falls below $200.
Horizon. 1-3 yr $244.59 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $358.11 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $531.23 if current growth sustains into durable earnings power.
17. CVSA — Covista Inc. · score 80.7
Education & Training Services · price $115.82 · 1Y $156.25 · 5Y $228.77 · 10Y $339.36
FCF $336m C · Rev +9.7% B · D/E 0.54 B+ · P/E 16.9x B+ · PEG 0.88 B+
Why now. Covista’s growth engine is its Chamberlain and Walden online health‑professionals programs, which are scaling faster than the broader education market. The business is delivering 12.3% profit margin, 17.2% ROE and a PEG of 0.88, all on a solid free‑cash‑flow base of $336 m (TTM). Those fundamentals prove the compounding power of its accredited, high‑touch online degrees and the thesis hinges on continued enrollment expansion in the health‑services sector.
Moat. Covista’s moat lies in its accredited degree ecosystem across Chamberlain University, Walden University and the Medical & Veterinary segment, which creates high switching costs for students and employers who rely on recognized credentials. The integrated online platform and regulatory approvals lock in a pipeline of nursing and health‑professionals, a barrier that new entrants cannot replicate quickly.
Risk. The bear case focuses on the modest 9.7% YoY revenue growth, which may stall if enrollment demand softens, and a debt‑to‑equity of 0.54 that could limit flexibility in a tightening credit environment. A P/E of 16.9, while not extreme, suggests the market has already priced in growth, so a slowdown would compress multiples. A sharp drop in enrollment or a rise in regulatory scrutiny would trigger the 52‑week low of $86.97 as a confirmation of the downside.
Horizon. 1-3 yr $156.25 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $228.77 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $339.36 if current growth sustains into durable earnings power.
18. MELI — MercadoLibre, Inc. · score 79.2
Internet Retail · price $1843.19 · 1Y $2,204 · 5Y $3,228 · 10Y $4,788
FCF $11.8b A- · Rev +36.4% A · D/E 1.70 C+ · P/E 48.7x C · PEG 1.14 B+
Why now. MercadoLibre's integrated ecosystem, particularly the synergistic growth of Mercado Libre Marketplace and Mercado Pago, positions it for continued outperformance in Latin America. With revenue growth at a staggering 36.4% FY YoY and a robust $11.8b in free cash flow, MELI is compounding capital efficiently, reflected in its healthy 8.6% profit margin. The crux of the thesis rests on the persistent expansion and deepening penetration of its commerce and financial technology platforms across its core markets.
Moat. MELI's durable edge stems from the powerful network effects created by its comprehensive financial technology solution platform, Mercado Pago, which is deeply integrated with the Mercado Libre Marketplace. This ecosystem fosters high switching costs for users and sellers, driving the company's exceptional 26.4% Return on Equity by efficiently monetizing transactions and services like Mercado Credito and Mercado Envios across its vast user base.
Risk. The primary bear case against MELI centers on the intense competitive landscape across its key markets in online commerce and financial technology, which could pressure its premium valuation. A high P/E of 48.7 and a Beta of 1.34 suggest significant growth expectations and market sensitivity, leaving little room for execution missteps. A sustained deceleration in revenue growth significantly below the current 36.4% or a material contraction in its 8.6% profit margin would confirm that competitive pressures are eroding its market dominance.
Horizon. 1-3 yr $2,204 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,228 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $4,788 if current growth sustains into durable earnings power.
19. PODD — Insulet Corporation · score 79.2
Medical Devices · price $159.28 · 1Y $236.83 · 5Y $346.75 · 10Y $514.38
FCF $416m C · Rev +31.9% A · D/E 0.78 C+ · P/E 37.2x C+ · PEG 1.42 B
Why now. The Omnipod 5 automated insulin delivery system is unlocking a new wave of adoption as patients demand closed‑loop convenience, and Insulet’s 31.9% FY revenue growth validates that demand. Coupled with a 10.4% profit margin and ROE of 23.2%, the business is compounding earnings faster than most med‑tech peers, making the current price a launchpad for sustained upside.
Moat. Insulet’s moat rests on the integrated Omnipod platform—its pod embeds a proprietary AID algorithm and Bluetooth link to third‑party CGMs, creating a seamless, lock‑in experience that rivals can’t replicate without costly FDA pathways and hardware redesign. The high ROE stems from pricing power in a niche, reimbursed diabetes market where switching costs are steep for patients accustomed to the pod’s convenience.
Risk. The bull case hinges on continued Omnipod adoption, but a P/E of 37.2 signals the market has already priced in lofty growth; any slowdown from the current 31.9% revenue pace or margin compression would force a re‑rating. A bear signal would be a dip in profit margin below 9% or a rise in debt‑to‑equity above 1.0, eroding the ROE advantage.
Horizon. 1-3 yr $236.83 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $346.75 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $514.38 if current growth sustains into durable earnings power.
20. APP — AppLovin Corporation · score 78.5
Advertising Agencies · price $452.73 · 1Y $654.60 · 5Y $958.40 · 10Y $1,422
FCF $4.4b B · Rev +66.4% A · D/E 1.63 C · P/E 39.4x C+ · PEG 1.39 B
Why now. APP's MAX in‑app bidding platform is the growth engine that will keep revenue compounding as mobile developers migrate to real‑time auctions, delivering 66.4% YoY revenue growth, 64.3% profit margin and $4.4B free cash flow—a cash‑rich engine that fuels reinvestment and share‑price upside. The thesis rests on the relentless shift to programmatic mobile inventory, which locks in high‑margin spend on MAX.
Moat. MAX creates a two‑sided network effect: publishers receive higher eCPMs from the real‑time competitive auction, while developers gain instant access to premium inventory, making switching costly. Coupled with Adjust's analytics lock‑in, APP locks in both supply and demand sides, a moat that competitors cannot replicate quickly without massive data and integration investments.
Risk. The stock trades at a lofty P/E of 39.4 and a high beta of 2.48, reflecting market pricing of growth that could stall; a slowdown in revenue growth or margin compression would force a re‑rating. Bears watch the debt‑to‑equity of 1.63 as a lever that could amplify downside if cash flow falters. A breach of the 52‑week low near $343 would confirm the risk narrative.
Horizon. 1-3 yr $654.60 (analyst consensus (n=30)) — fundamentals + valuation re-rating. 5 yr $958.40 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $1,422 if current growth sustains into durable earnings power.
21. FIVE — Five Below, Inc. · score 78.5
Specialty Retail · price $193.03 · 1Y $260.33 · 5Y $381.15 · 10Y $565.42
FCF $505m C+ · Rev +25.9% A- · D/E 0.86 B · P/E 24.3x B · PEG 0.98 B+
Why now. Five Below’s explosive 25.9% FY revenue growth is powered by its ever‑expanding teen‑and‑pre‑teen merchandise aisle – from novelty candy to loungewear – which fuels repeat traffic in its 1,200‑plus stores; the business translates that top‑line surge into a healthy 8.7% profit margin and a solid ROE of 19%, proving the model scales profitably. The compounding engine is the relentless rollout of new product categories that keep the value‑seeking Gen‑Z shopper coming back, ensuring growth persists as long as the brand remains the go‑to “fun‑first” destination.
Moat. The moat lies in Five Below’s curated, low‑price assortment that locks in a price‑sensitive teen demographic who view the store as a destination for impulse buys across candy, accessories, and décor – a mix that is hard for big‑box rivals to replicate without diluting their own brand. Its 1,200‑plus footprint creates a network effect: each new store amplifies brand awareness and cross‑selling opportunities, while the high turnover of inexpensive SKUs drives inventory efficiency and pricing power, underpinning the 19% ROE.
Risk. The bear case centers on the elevated valuation – a forward P/E of 24.3 versus peers – which assumes growth will not decelerate; any slowdown from the current 25.9% revenue surge would compress margins and pressure the 0.86 debt‑to‑equity ratio, especially if rent costs rise. A miss on top‑line growth or margin expansion would trigger a sell‑off, and the stock would likely retreat toward its 52‑week low of $130, confirming the downside thesis.
Horizon. 1-3 yr $260.33 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $381.15 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $565.42 if current growth sustains into durable earnings power.
22. DECK — Deckers Outdoor Corporation · score 78.4
Footwear & Accessories · price $106.53 · 1Y $127.81 · 5Y $187.13 · 10Y $277.59
FCF $1.1b C+ · Rev +9.8% B · D/E 0.15 A · P/E 15.2x A- · PEG 1.32 B
Why now. Deckers' HOKA performance‑running franchise is scaling faster than the broader footwear market, delivering 9.8% revenue growth YoY, 41% ROE, and $1.1 B of free cash flow on a $14.8 B market cap, which together fuel a compounding earnings engine that can sustain double‑digit returns for years. The thesis hinges on HOKA’s premium pricing power and expanding global distribution, which keep margins high and cash generation robust.
Moat. HOKA’s differentiated cushioning technology and premium positioning lock in performance‑oriented consumers who are reluctant to switch to lower‑priced alternatives, creating a pricing moat that translates into the company’s 41% ROE. Coupled with a low debt‑to‑equity of 0.15, Deckers can reinvest cash without financing constraints, reinforcing its competitive edge.
Risk. A slowdown in premium‑segment demand or aggressive pricing wars from rivals could compress margins, and the stock’s beta of 1.17 amplifies any market pullback; the current P/E of 15.2, while reasonable, may already price in growth, so a revenue growth dip below 9% would trigger a re‑rating. A sustained drop in free cash flow below $1 B would confirm the bear case.
Horizon. 1-3 yr $127.81 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $187.13 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $277.59 if current growth sustains into durable earnings power.
23. NFLX — Netflix, Inc. · score 78.3
Entertainment · price $73.68 · 1Y $112.17 · 5Y $164.23 · 10Y $243.62
FCF $11.9b A- · Rev +16.7% B+ · D/E 0.54 B · P/E 23.8x B · PEG 1.44 B
Why now. Netflix’s global streaming platform is locked into a relentless subscriber expansion engine, driven by its ever‑growing library of TV series, documentaries, feature films and games that keep members glued to the service. The business is scaling at 16.7% revenue growth YoY, converting that into a razor‑thin 28.5% profit margin and an eye‑popping 43% ROE, proving that each new subscriber adds disproportionate earnings. The thesis hinges on the compounding power of its content‑driven stickiness, which should keep cash conversion high and valuation multiples reasonable.
Moat. Netflix’s moat lives in its proprietary content ecosystem—original series, documentaries and games that are exclusive to its platform—creating a high switching cost for members who have invested time in binge‑watching. This content advantage fuels pricing power, evident in a 43% ROE, because the company can command higher subscription fees while competitors scramble to match its library depth. The seamless delivery across TVs, set‑top boxes and mobile devices further entrenches the service in everyday viewing habits, a distribution edge hard to replicate quickly.
Risk. The bear case centers on intensifying competition from other streaming services that can erode Netflix’s subscriber growth, while its P/E of 23.8 is already elevated for a growth name, leaving little room for a slowdown before the valuation looks stretched. A dip in revenue growth below the current 16.7% or margin compression would validate the risk, and a sustained rise in the debt‑to‑equity ratio beyond 0.54 would signal financial strain. The key signal to watch is a quarterly revenue growth miss combined with a widening spread between Netflix’s beta‑adjusted cost of capital and its earnings yield.
Horizon. 1-3 yr $112.17 (analyst consensus (n=44)) — fundamentals + valuation re-rating. 5 yr $164.23 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $243.62 if current growth sustains into durable earnings power.
24. MU — Micron Technology, Inc. · score 77.1
Semiconductors · price $904.28 · 1Y $1,486 · 5Y $2,176 · 10Y $3,227
FCF $26.2b A · Rev +167.0% A · D/E 0.06 A- · P/E 20.4x B+ · PEG 0.14 A
Why now. Micron is a compounding growth engine, leveraging its leadership in high-bandwidth memory (HBM) and data center memory products to capture explosive demand from the Cloud and Core Data Center Business Units. With an astounding 167% FY YoY revenue growth and a remarkably low 0.14 PEG ratio, the market is severely underpricing its compounding power, especially given its 55.9% profit margins. The crux of the thesis rests on the sustained, exponential growth in data consumption and AI workloads driving demand for its specialized memory solutions.
Moat. Micron's durable edge stems from its deep intellectual property and manufacturing expertise in critical memory products like high-bandwidth memory (HBM) and advanced dynamic random access memory components. This specialized capability, essential for the Cloud and Core Data Center Business Units, allows for pricing power and efficient capital deployment, evidenced by its exceptional 50.1% Return on Equity, which competitors cannot quickly replicate due to the immense R&D and capital expenditure required.
Risk. The primary bear case for Micron centers on the inherent cyclicality of the semiconductor memory market, where periods of oversupply can rapidly erode pricing power despite strong demand. Its high 2.14 Beta underscores its sensitivity to broader market downturns and sector-specific corrections. A concrete signal confirming this bear case would be a material deceleration in demand for high-bandwidth memory or data center memory products, leading to a sharp contraction in its impressive profit margins.
Horizon. 1-3 yr $1,486 (analyst consensus (n=42)) — fundamentals + valuation re-rating. 5 yr $2,176 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $3,227 if current growth sustains into durable earnings power.
25. YUMC — Yum China Holdings, Inc. · score 76.4
Restaurants · price $43.17 · 1Y $61.34 · 5Y $89.81 · 10Y $133.23
FCF $931m C+ · Rev +6.7% C+ · D/E 0.38 A- · P/E 16.5x B+ · PEG 1.08 B+
Why now. Yum China's KFC franchise is accelerating digital order volumes, driving a 6.7% YoY revenue growth while delivering a 7.8% profit margin on a $14.9B market cap; the combination of low beta (0.09) and a PEG of 1.08 signals that earnings growth is both sustainable and undervalued, making the compounding engine of its high‑margin quick‑service restaurants the core of the upside.
Moat. The KFC and Pizza Hut brands in China benefit from a dense, proprietary delivery network and franchised real‑estate footprint that locks in high‑traffic locations, creating switching costs for both customers and franchisees; this operational scale underpins a 17.4% ROE, reflecting pricing power and cost efficiencies that rivals cannot replicate quickly.
Risk. A slowdown in Chinese consumer spending or aggressive price wars could compress the already modest 7.8% margin, and the 0.38 debt‑to‑equity ratio, while low, may rise if expansion accelerates, eroding returns; a breach of the 52‑week low ($40.15) would confirm margin pressure and validate the bear case.
Horizon. 1-3 yr $61.34 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $89.81 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $133.23 if current growth sustains into durable earnings power.
26. FISV — Fiserv, Inc. · score 75.9
Sector n/a · price $50.36 · 1Y $67.56 · 5Y $98.91 · 10Y $146.72
FCF $4.1b B · Rev +9.3% B · D/E n/a · P/E 8.5x A- · PEG 2.37 C
Why now. Fiserv’s core payments platform is locked into a $4.1B free cash flow engine ($4.1B) that fuels a 9.3% revenue CAGR (+9.3%) while delivering a 19.7% profit margin (~20%); the combination of low‑multiple valuation (PE 8.5x) and a durable merchant‑network creates a compounding engine that will keep cash conversion rising for years. The thesis hinges on the continued expansion of digital transaction volumes that lock in recurring fees and drive margin expansion.
Moat. The moat lives in Fiserv’s entrenched processing stack that serves millions of merchants and banks, creating switching costs that are hard to replicate. Its pricing power, reflected in a 12.2% ROE, stems from category leadership in integrated payments and data‑driven services, which lock in long‑term contracts and generate sticky revenue streams.
Risk. The bear case points to a decelerating growth runway – revenue growth has slipped to just 9.3% YoY and the consensus hold rating (2.67/5) signals skepticism about sustaining that pace. A pull‑back in merchant spend or aggressive pricing wars could compress the 19.7% margin, and a break below the 52‑week low of $47.04 would confirm a valuation correction. The key signal would be a quarterly revenue miss that pushes the PE back toward double‑digit levels.
Horizon. 1-3 yr $67.56 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $98.91 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $146.72 if current growth sustains into durable earnings power.
27. DEO — Diageo plc · score 75.6
Beverages - Wineries & Distilleries · price $82.21 · 1Y $101.14 · 5Y $148.08 · 10Y $219.67
FCF n/a · Rev +4.8% C+ · D/E 1.77 C · P/E 19.0x B · PEG 0.80 A-
Why now. Diageo’s premium spirits franchise – anchored by Johnnie Walker Scotch and Guinness stout – is compounding earnings as it leverages pricing power in mature markets, evidenced by a ROE of 40.5%, a PEG of 0.8 and a revenue growth of 4.8% YoY. The combination of ultra‑high margin categories and a low‑beta balance sheet means earnings will keep expanding faster than peers, and the thesis hinges on that sustained premium pricing advantage.
Moat. Diageo commands pricing power through category leadership in Scotch whisky and premium beer, allowing it to out‑price rivals without losing shelf share across its global distribution network. This pricing edge, coupled with a 40.5% ROE, stems from entrenched relationships with on‑trade and off‑trade customers who face high switching costs to alternative premium brands.
Risk. The bears point to a debt‑to‑equity ratio of 1.77, which limits financial flexibility, and a modest 4.8% revenue growth that could stall if premium demand softens, making the current P/E of 19 appear stretched for a slower‑growing consumer staple. A breach of the 52‑week low ($72.45) would signal margin pressure and validate the debt risk, derailing the compounding story.
Horizon. 1-3 yr $101.14 (analyst consensus (n=7)) — fundamentals + valuation re-rating. 5 yr $148.08 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $219.67 if current growth sustains into durable earnings power.
28. ULTA — Ulta Beauty, Inc. · score 75.4
Specialty Retail · price $466.14 · 1Y $623.58 · 5Y $912.99 · 10Y $1,354
FCF $1.1b C+ · Rev +11.3% B · D/E 0.89 B · P/E 17.5x B+ · PEG 1.63 C+
Why now. Ulta’s relentless expansion of its in‑store salon services is the engine that will keep earnings compounding, because each new chair adds high‑margin recurring revenue while driving product sales. The business is growing revenue at 11.3% YoY, converting that into a 9.4% profit margin and generating $1.1B of free cash flow on a $20.0B market cap, delivering a 5‑year ROE of 46%. The thesis hinges on the salon‑driven stickiness that lets Ulta out‑pace peers as consumers spend more on services and the associated product upsell.
Moat. Ulta’s moat lives in its integrated beauty ecosystem: the combination of a full‑line retail assortment with on‑site professional salons creates a one‑stop beauty destination that locks in high‑spending customers and raises average transaction size. The 46% ROE reflects pricing power derived from category leadership in both cosmetics and salon services, a mix competitors can’t replicate quickly without comparable store footprints and service expertise.
Risk. The bear case centers on a potential slowdown in salon traffic as consumers shift to DIY at‑home solutions, which would compress the 9.4% profit margin and pressure the 11.3% revenue growth rate. A P/E of 17.5 is modest but still above the sector average, implying the market has already priced in growth; a margin contraction or a dip in salon revenue would force the stock toward the 52‑week low of $443.6. The key signal for bears would be a quarterly miss on salon‑related sales and a widening debt‑to‑equity above 0.89.
Horizon. 1-3 yr $623.58 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $912.99 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $1,354 if current growth sustains into durable earnings power.
29. META — Meta Platforms, Inc. · score 75.3
Internet Content & Information · price $681.31 · 1Y $826.63 · 5Y $1,210 · 10Y $1,795
FCF $48.3b A · Rev +26.2% A- · D/E 0.36 B+ · P/E 24.8x B · PEG 0.97 B+
Why now. Meta’s Family of Apps is a cash‑generating engine that will keep compounding as Instagram Reels and Facebook Marketplace capture ever‑larger slices of global ad spend. The business is growing revenue at 26.2% YoY, converting that into a 32.8% profit margin and delivering $48.3 B of free cash flow – a rare combination at a $1.7 T market cap. The compounding loop of user engagement, data‑driven ad pricing and relentless margin expansion is the single driver that will lift the stock toward its consensus target.
Moat. Meta’s moat lives in the network effects of its Family of Apps: billions of users generate data that fuels superior ad targeting, giving the company pricing power that translates into a 29% ROE. Switching costs are high because users and advertisers are entrenched across Facebook, Instagram and Messenger, and no rival can replicate the depth of cross‑platform data at scale without massive user bases.
Risk. The bear case hinges on a valuation premium – a forward P/E of 24.8x for a growth name – that leaves little room for a slowdown in the 26% revenue growth rate. A higher beta of 1.25 amplifies market‑wide risk, and any erosion of ad spend to competitors would compress the 32.8% margin. A sustained dip below the 52‑week low of $520.26 would confirm the overvaluation and trigger a sell‑off.
Horizon. 1-3 yr $826.63 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $1,210 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $1,795 if current growth sustains into durable earnings power.
30. EME — EMCOR Group, Inc. · score 74.3
Engineering & Construction · price $769.72 · 1Y $1,000 · 5Y $1,263 · 10Y $1,619
FCF $1.1b C+ · Rev +18.3% B+ · D/E 0.13 A- · P/E 25.9x B+ · PEG 0.41 A
Why now. Engineering & Construction · market cap $34.3b. 19% off the 52-week high of $951.96. Revenue growing +18%, comfortably above the S&P median. PEG 0.41 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $1,000 (implying +30% upside).
Moat. ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $1,000 (analyst consensus (n=7)) — multiple re-rating thesis requires a catalyst. 5 yr $1,263 at ~10% CAGR — dividend + buyback compounding. 10 yr $1,619 if the moat survives secular pressure.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.